Related Experiment Video

Updated: Aug 7, 2026

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

Is digitalis a therapy for breast carcinoma?

B Stenkvist1

  • 1Institute of Pathology, University of Uppsala, Uppsala, Sweden.

Oncology Reports
|April 16, 1999
PubMed

Insights

Digitalis treatment in breast carcinoma patients showed a significantly lower death rate and reduced tumor proliferation. These findings suggest digitalis derivatives may offer promising therapeutic potential for cancer drug design.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiology

Background:

  • Previous studies indicated digitalis affects breast carcinoma cytometric features and recurrence.
  • Current research focuses on the anti-proliferative and apoptosis-inducing effects of digitalis glycosides on cancer cells.
  • Digitalis, a cardiac glycoside, has a long history of medicinal use.

Purpose of the Study:

  • To conduct a long-term follow-up study on breast carcinoma patients treated with digitalis.
  • To evaluate the impact of digitalis on mortality rates and tumor characteristics in breast cancer patients.
  • To explore the potential of digitalis derivatives in cancer drug development.

Main Methods:

  • Long-term follow-up (22.3 years) of 175 breast carcinoma patients.
  • Comparison of outcomes between 32 patients on digitalis treatment and those not on digitalis.
  • Analysis of death rates, tumor proliferation, and aneuploidy.

Main Results:

  • A significantly lower death rate from breast carcinoma in patients on digitalis (6%) compared to those not on digitalis (34%).
  • Reduced tumor proliferation and aneuploidy observed in patients treated with digitalis.
  • Statistical significance was noted, though limited by a low number of deaths in the digitalis group.

Conclusions:

  • Digitalis derivatives warrant serious consideration for cancer drug design due to observed effects on cancer cells.
  • The potential of digitalis in cancer therapy may surpass current adjuvant treatments in efficacy and side-effect profiles.
  • Further research into digitalis's role in oncology is crucial and holds significant promise.

More Related Videos

Intraductal Delivery to the Rabbit Mammary Gland06:30

Intraductal Delivery to the Rabbit Mammary Gland

Published on: March 9, 2017

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...